11:08 AM
 | 
Mar 13, 2018
 |  BC Extra  |  Clinical News

AbbVie's elagolix meets in second Phase III for uterine fibroids

AbbVie Inc. (NYSE:ABBV) said elagolix (ABT-620) met the primary and all ranked secondary endpoints in the Phase III ELARIS UF-II (M12-817) trial, the second of two replicate Phase III trials of the candidate to treat uterine fibroids. AbbVie said a commercial launch of elagolix to treat uterine fibroids is planned for 2020, but the company declined to disclose...

Read the full 267 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >